Alyftrek
·
- Prescription status not stated
- Breathing, airways, allergies and cough
- Active substance
- Deutivacaftor / tezacaftor / vanzacaftor
- Made by
- Vertex Pharmaceuticals (Ireland) Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Alyftrek tablets are indicated for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one non-Class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see sections 4.2 and 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Vertex Pharmaceuticals (Ireland) Limited |
|---|---|
| Active substance | Deutivacaftor / tezacaftor / vanzacaftor |
| Used in | Breathing, airways, allergies and cough |
| Classification | R07AX33 · Breathing, airways, allergies and cough |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-06-30 |
| Last updated by the regulator | 2026-08-19 |
| EMA product number | EMEA/H/C/006382 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).